Tiens Biotech Group (USA), Inc. (BULLETIN BOARD: TBGU) , which operates primarily through its subsidiary Tianjin Tianshi Biological Development Co., Ltd (”Biological”), today announced that Jinyuan Li, Chairman, President and CEO of the company, has been named One of the Top Ten Men of the Year for 2004 in China. He received the award in recognition for his significant achievements in corporate management and in the field of economics. The award was presented jointly by China Domestic and Foreign Celebrity Culture Seminar, China Contemporary Celebrity Academy, and China Fortune Forum Journal. This ceremony was held in the Great Hall of the People in Beijing, China on January 8, 2005. The forum was to honor corporate executives whose insights have benefited Chinese society and helped promote the development of China as a worldwide business leader. Jinyuan Li, Chairman, President and CEO of Tiens Biotech Group (USA), Inc., said, “I am greatly honored to have been selected to receive this most prestigious award. I am proud of being part of the recognition China is receiving for its expansion in a broad spectrum of key industries and the growing acceptance of our fine products and services throughout the world.” About Tiens Biotech Group (USA), Inc. Tiens Biotech Group (USA), Inc. (”the Company” or “Tiens”) conducts its main business through its subsidiary Tianjin Tianshi Biological Development Co., Ltd (”Biological”), which has its headquarters in Beijing, China, and production plants in Tianjin, China’s third largest city. In September 2003, Tiens completed a reverse merger with Strategika, Inc. and received approval for the company’s formal name and symbol changes in February 2004.In China, Tiens sells its products through 22 branches, representative offices and chain stores and 12 domestic affiliate companies of its affiliate company, Tianjin Tianshi Biological Engineering Co., Ltd. Internationally, the Company markets its products to approximately 90 countries on six continents. Tiens Biotech Group (USA), Inc. is primarily engaged in the research, development, manufacturing and marketing of healthcare products including herbal products, vitamin and mineral supplements and personal care. Since its establishment, the company has developed 7 major product series and produced 45 types of healthcare products. Among these are 27 healthcare food products, 23 of which have obtained the “Health Food Certificates” issued by the PRC Ministry of Health. The 7 major product series are: High-Calcium Series, Immune System Adjustment Series, Nutrient Supplements Series, Cholesterol Adjustment Series, High-Fiber Series, Heart and Brain Improvement Series and Personal Care Series. Under the High-Calcium series, Tiens has conducted extensive research and developed Tianshi Super Calcium with Metabolic Factors and Tianshi Super Calcium Powder for Children, which have been awarded patents from the State Intellectual Properties Office in China with respective patent numbers of ZL97115067.2 and ZL97115068.0. Tiens Biotech Group (USA), Inc. (BULLETIN BOARD: TBGU) is a corporation organized under the laws of the State of Delaware and is classified under the industrial standard of pharmaceutical preparations. Certain statements in this press release constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities and Exchange Act of 1934. Such forward- looking statements, including the Company’s financial results for the nine months ended September 30, 2004, are not necessarily indicative of future financial results, and may involve known and unknown risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Tiens Biotech Group (USA), Inc. (”the Company”), or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward- looking statements. The Company’s future operating results are dependent upon many factors, including but not limited to the Company’s ability to: (i) obtain sufficient capital or a strategic business arrangement to fund its expansion plans; (ii) build the management and human resources and infrastructure necessary to support the growth of its business; (iii) competitive factors and developments beyond the Company’s control; and (iv) other risk factors discussed in the Company’s periodic filings with the Securities and Exchange Commission which are available for review at http://www.sec.gov/ under “Search for Company Filings.” Quelle: Tiens Biotech Group (USA), Inc.
January 26th, 2005 by site admin | No Comments »